

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims

1. (Currently Amended): A method of modifying beta-amyloid-induced vasoactivity in individuals with Alzheimer's Disease [and] or other vascular-related diseases or disorders, [such as] in which said vascular-related diseases or disorders are selected from the group consisting of cerebral amyloid angiopathy, vascular amyloidosis, hypertension [or] and vasospasm associated with severe post-traumatic head injury, comprising antagonizing the secretory phospholipase A2/arachidonic acid/5-lipoxygenase/cyclo-oxygenase-2 pro-inflammatory pathway by administering a pharmaceutically effective amount of a secretory phospholipase A2 inhibitor to the individual in an amount ranging from between [about] 0.1 ng to 10 mg/kg body weight/day.

2. (Previously Presented): The method according to claim 1, further defined as upregulating the soluble A β pro-inflammatory pathway.

3. (Previously Presented): The method according to claim 1, further defined as down-regulating a soluble A β pro-inflammatory pathway.

4. 4-21. (Canceled)